Benjamin Rengstl

1.4k total citations
24 papers, 465 citations indexed

About

Benjamin Rengstl is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Benjamin Rengstl has authored 24 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 16 papers in Immunology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Benjamin Rengstl's work include CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immune Cell Function and Interaction (8 papers). Benjamin Rengstl is often cited by papers focused on CAR-T cell therapy research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immune Cell Function and Interaction (8 papers). Benjamin Rengstl collaborates with scholars based in Germany, Netherlands and Austria. Benjamin Rengstl's co-authors include Sebastian Newrzela, Sylvia Hartmann, Martin‐Leo Hansmann, Claudia Döring, Ralf Küppers, Kathrin Warner, Michael A. Rieger, Xavier Sagaert, Dorotheé von Laer and Chris De Wolf‐Peeters and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Benjamin Rengstl

24 papers receiving 462 citations

Peers

Countries citing papers authored by Benjamin Rengstl

Since Specialization

Citations

This map shows the geographic impact of Benjamin Rengstl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Rengstl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Rengstl more than expected).

Fields of papers citing papers by Benjamin Rengstl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Rengstl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Rengstl. The network helps show where Benjamin Rengstl may publish in the future.

Co-authorship network of co-authors of Benjamin Rengstl

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Rengstl. A scholar is included among the top collaborators of Benjamin Rengstl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Rengstl. Benjamin Rengstl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA35 BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac) 2023 ·Annals of Oncology ·Andréas Mackensen, (unknown), Winfried Alsdorf, Christian Koenecke, (unknown), Peter Borchmann, Daniel Heudobler, Andreas Busse, Sebastian Klobuch, Nadine Kutsch, Fabian Müller, Carsten Bokemeyer, (unknown), (unknown), (unknown), (unknown), (unknown), Benjamin Rengstl, Özlem Türeci, Uğur Şahin	1
2	351 Claudin 6 Expression in Atypical Teratoid/Rhabdoid Tumors is a Target for CAR-T Cell Therapy 2023 ·Neurosurgery ·(unknown), (unknown), (unknown), (unknown), Benjamin Rengstl, (unknown), Alexander W. Tucker, Phillip B. Storm, (unknown), Jessica Foster	1
3	CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product. 2023 ·Journal of Clinical Oncology ·Andréas Mackensen, John B.A.G. Haanen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Daniel Heudobler, Peter Borchmann, Carsten Bokemeyer, Sebastian Klobuch, Nadine Kutsch, Fabian Müller, Alexander Desuki, Florian Lüke, Erol Wiegert, (unknown), (unknown), Benjamin Rengstl, Liane Preußner, Özlem Türeci, Uğur Şahin	5
4	A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination 2022 ·Cancer Research Communications ·Matthias Birtel, Ralf-Holger Voss, Katharina Reinhard, Benjamin Rengstl, (unknown), Kristina Michel, (unknown), Bodo Tillmann, (unknown), M Suchan, Matthias Theobald, Petra Oehm, Özlem Türeci, Uğur Şahin	16
5	LBA1 BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+ advanced solid tumors 2021 ·Annals of Oncology ·J.B.A.G. Haanen, Andréas Mackensen, Christian Koenecke, Winfried Alsdorf, Alexander Desuki, Eva Wagner-Drouet, Daniel Heudobler, Peter Borchmann, Erol Wiegert, Carsten‐Oliver Schulz, Benjamin Rengstl, Liane Preußner, Ö. Türeci, Uğur Şahin	7
6	CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma 2018 ·Oncotarget ·(unknown), Benjamin Rengstl, (unknown), (unknown), (unknown), Thorsten Friedel, Irene C. Schneider, Sebastian Newrzela, Martin‐Leo Hansmann, Christian J. Buchholz, (unknown)	19
7	Small and big Hodgkin-Reed-Sternberg cells of Hodgkin lymphoma cell lines L-428 and L-1236 lack consistent differences in gene expression profiles and are capable to reconstitute each other 2017 ·PLoS ONE ·Benjamin Rengstl, (unknown), Claudia Döring, (unknown), (unknown), Katrin Bankov, Marco Herling, Sebastian Newrzela, Martin‐Leo Hansmann, Sylvia Hartmann	4
8	Tumor-infiltrating HLA-matched CD4⁺T cells retargeted against Hodgkin and Reed–Sternberg cells 2016 ·OncoImmunology ·Benjamin Rengstl, (unknown), (unknown), Claudia Döring, (unknown), Kathrin Warner, P. S. A. Becker, (unknown), (unknown), (unknown), (unknown), Christian Seidl, Sylvia Hartmann, Hinrich Abken, Ralf Küppers, Martin‐Leo Hansmann, Sebastian Newrzela	10
9	Concepts in mature T-cell lymphomas – highlights from an international joint symposium on T-cell immunology and oncology 2016 ·Leukemia & lymphoma ·Marco Herling, Benjamin Rengstl, René Scholtysik, Sylvia Hartmann, Ralf Küppers, Martin‐Leo Hansmann, Hans H. Diebner, Ingo Roeder, Hinrich Abken, Sebastian Newrzela, Jörg Kirberg	1
10	A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma 2016 ·Oncotarget ·Bianca Schuhmacher, Benjamin Rengstl, Claudia Döring, (unknown), Sebastian Newrzela, Uta Brunnberg, Hans Michael Kvasnicka, Martine Vornanen, Ralf Küppers, Martin‐Leo Hansmann, Sylvia Hartmann	10
11	Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma 2015 ·Leukemia ·Sylvia Hartmann, Bianca Schuhmacher, Tobias Rausch, Laphalle Fuller, Claudia Döring, Marc A. Weniger, Anna Lollies, (unknown), Lorenz Thurner, Benjamin Rengstl, Uta Brunnberg, Martine Vornanen, Michael Pfreundschuh, Vladimı́r Beneš, Ralf Küppers, Sebastian Newrzela, M-L Hansmann	58
12	On the origin of giant cells in Hodgkin lymphoma 2014 ·Communicative & Integrative Biology ·Benjamin Rengstl, Michael A. Rieger, Sebastian Newrzela	7
13	Nodular Lymphocyte Predominant Hodgkin Lymphoma and T cell/Histiocyte Rich Large B Cell Lymphoma Endpoints of a Spectrum of one Disease? 2014 ·Klinische Pädiatrie ·Sylvia Hartmann, Claudia Döring, (unknown), Benjamin Rengstl, Sebastian Newrzela, Thomas Tousseyn, Xavier Sagaert, Maurilio Ponzoni, Fabio Facchetti, C. De Wolf‐Peeters, Christian Steidl, R. D. Gascoyne, Ralf Küppers, ML Hansmann	1
14	Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma 2013 ·Modern Pathology ·Sylvia Hartmann, (unknown), Benjamin Rengstl, Claudia Döring, Sebastian Newrzela, Hans‐Reinhard Brodt, Timo Wolf, Martin‐Leo Hansmann	33
15	Mature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1 2013 ·Molecular Therapy ·(unknown), Benjamin Rengstl, Alexander Muik, Mina Petkova, (unknown), (unknown), Kathrin Warner, Giuliano Crispatzu, Martin‐Leo Hansmann, Marco Herling, Dorotheé von Laer, Sebastian Newrzela	23
16	Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma 2013 ·PLoS ONE ·(unknown), Christoph Renné, Erik Maronde, Marco Koch, Urszula Grabiec, Sonja Kallendrusch, Benjamin Rengstl, Sebastian Newrzela, Sylvia Hartmann, Martin‐Leo Hansmann, Faramarz Dehghani	27
17	Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease? 2013 ·PLoS ONE ·Sylvia Hartmann, Claudia Döring, (unknown), Benjamin Rengstl, Sebastian Newrzela, Thomas Tousseyn, Xavier Sagaert, Maurilio Ponzoni, Fabio Facchetti, Chris De Wolf‐Peeters, Christian Steidl, Randy D. Gascoyne, Ralf Küppers, Martin‐Leo Hansmann	78
18	Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed–Sternberg cells 2013 ·Proceedings of the National Academy of Sciences ·Benjamin Rengstl, Sebastian Newrzela, (unknown), (unknown), Frederic B. Thalheimer, (unknown), Kathrin Warner, Sylvia Hartmann, Timm Schroeder, Ralf Küppers, Michael A. Rieger, Martin‐Leo Hansmann	57
19	T-cell receptor diversity prevents T-cell lymphoma development 2012 ·Leukemia ·Sebastian Newrzela, (unknown), (unknown), Mina Petkova, Sylvia Hartmann, Benjamin Rengstl, Ashok Kumar, Hans‐Martin Jäck, Sebastian Gerdes, Ingo Roeder, M-L Hansmann, Dorotheé von Laer	35
20	Multiple Restrictions of Human Immunodeficiency Virus Type 1 in Feline Cells 2007 ·Journal of Virology ·Carsten Münk, Jörg Zielonka, (unknown), Björn‐Philipp Kloke, Benjamin Rengstl, Battenberg Marion, Francesca Bonci, Mauro Pistello, Martin Löchelt, Klaus Cichutek	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact